CNS Pharmaceuticals, Inc.

HOUSTON, TX · CIK 0001729427 · Biotech · Public

Small-molecule therapeutics for brain cancer and neurological diseases

cnspharma.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$23M
1 Form D · May 2026
5 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$22,525,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2088hC Bioscience—$12M
2089Eden Food International Inc.—$13M
2090General Translation, Inc.—$2.4M
2091CNS Pharmaceuticals, Inc.—$23M
2092CAYMAN CHEMICAL COMPANY, INCORPORATED——
2093Kairos Pharma, LTD.—$4.2M
2094MONON BIOVENTURES, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Faith CharlesDirector
  • Bettina CockroftDirector
  • Michal FisherDirector
  • Jeffry KeyesDirector
  • Rami LevinDirector · Executive Officer
  • Amy MaheryDirector
  • Steve O'LoughlinExecutive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.